We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » No New Cases of PML in Tysabri Patients, NIH Study Finds
No New Cases of PML in Tysabri Patients, NIH Study Finds
March 8, 2006
Patients who were treated with Biogen Idec and Elan’s multiple-sclerosis drug Tysabri displayed no new cases of progressive multifocal leukoencephalopathy (PML), a rare and deadly nerve disease that has been linked to the drug, an NIH study found.